Related references
Note: Only part of the references are listed.Long-term changes in short-interval intracortical facilitation modulate motor cortex plasticity and L-dopa-induced dyskinesia in Parkinson's disease
Andrea Guerra et al.
BRAIN STIMULATION (2022)
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy The PD MED Randomized Clinical Trial
Richard Gray et al.
JAMA NEUROLOGY (2022)
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study
Rosa De Micco et al.
NEUROLOGICAL SCIENCES (2022)
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study
Domiziana Rinaldi et al.
JOURNAL OF NEURAL TRANSMISSION (2021)
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
Giovanni Abbruzzese et al.
JOURNAL OF PARKINSONS DISEASE (2021)
SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease
Ana Gomez-Lopez et al.
BRAIN SCIENCES (2021)
The role of noradrenaline in cognition and cognitive disorders
Negin Holland et al.
BRAIN (2021)
Dopamine-dependent early synaptic and motor dysfunctions induced by a-synuclein in the nigrostriatal circuit
Alessandro Tozzi et al.
BRAIN (2021)
An updated calculator for determining levodopa-equivalent dose
D. Nyholm et al.
NEUROLOGICAL RESEARCH AND PRACTICE (2021)
Impulse control and related behaviors in Parkinson's disease with dementia
P. Martinez-Martin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Diagnosis and Treatment of Parkinson Disease A Review
Melissa J. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa
Roberto Cilia et al.
BRAIN (2020)
Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study
Christian Geroin et al.
JOURNAL OF NEURAL TRANSMISSION (2020)
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
Nobutaka Hattori et al.
PARKINSONISM & RELATED DISORDERS (2020)
EQUIDopa: A responsive web application for the levodopa equivalent dose calculator
Domen Verber et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2020)
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Sebastian Schade et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2020)
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside
Marika Alborghetti et al.
CURRENT NEUROPHARMACOLOGY (2019)
Dopamine restores cognitive motivation in Parkinson's disease
Sara McGuigan et al.
BRAIN (2019)
Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease
Andrea Guerra et al.
BRAIN STIMULATION (2019)
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease
Maria Laura Ester Bianchi et al.
NEUROLOGICAL SCIENCES (2019)
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia
Michele Morari et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders
Luigi Trojano et al.
NEUROLOGICAL SCIENCES (2018)
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study
Domiziana Rinaldi et al.
NEUROLOGICAL SCIENCES (2018)
Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain
Carlo Cattaneo et al.
ADVANCES IN THERAPY (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study
Nobutaka Hattori et al.
PARKINSONISM & RELATED DISORDERS (2018)
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients
Claudio Liguori et al.
SLEEP MEDICINE (2018)
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
Alberto J. Espay et al.
ANNALS OF NEUROLOGY (2018)
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
F. Gardoni et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia
Laura L. Frakey et al.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2017)
Cognitive decline in Parkinson disease
Dag Aarsland et al.
NATURE REVIEWS NEUROLOGY (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
Nadhir Litim et al.
NEUROPHARMACOLOGY (2017)
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis
Carlo Cattaneo et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease
Carlo Cattaneo et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Anthony H. V. Schapira et al.
JAMA NEUROLOGY (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review
Karin Wirdefeldt et al.
CNS DRUGS (2016)
mGlu5, Dopamine D-2 and Adenosine A(2A) Receptors in L-DOPA-induced Dyskinesias
Nicolas Morin et al.
CURRENT NEUROPHARMACOLOGY (2016)
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial
Daniel Weintraub et al.
MOVEMENT DISORDERS (2016)
Apomorphine - pharmacological properties and clinical trials in Parkinson's disease
Peter Jenner et al.
PARKINSONISM & RELATED DISORDERS (2016)
Selegiline induces a wake promoting effect in rats which is related to formation of its active metabolites
Christoffer Bundgaard et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2016)
Improvement in Language Function Correlates with Gait Improvement in Drug-naive Parkinson's Disease Patients Taking Dopaminergic Medication
Hidetomo Murakami et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE
Carlo Cattaneo et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Cognitive decline in Parkinson's disease: the complex picture
Roberta Biundo et al.
NPJ PARKINSONS DISEASE (2016)
Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease
Alan King Lun Liu et al.
ACTA NEUROPATHOLOGICA (2015)
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients
P. Barone et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Dopamine Signals and Physiological Origin of Cognitive Dysfunction in Parkinson's Disease
Masayuki Matsumoto
MOVEMENT DISORDERS (2015)
Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies
Keith A. Wesnes et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2015)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Cognitive Executive Impairment and Dopaminergic Deficits in De Novo Parkinson's Disease
Francoise J. Siepel et al.
MOVEMENT DISORDERS (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
Joseph Jankovic et al.
PARKINSONISM & RELATED DISORDERS (2014)
Dementia and mild cognitive impairment in Parkinson's disease: a review
Yamile Bocanegra et al.
REVISTA DE NEUROLOGIA (2014)
Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
Lawrence W. Elmer
PARKINSONISM & RELATED DISORDERS (2013)
Behavioral disorders in Parkinson's disease: The role of dopamine
Francesca Antonelli et al.
PARKINSONISM & RELATED DISORDERS (2013)
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease
Nandakumar S. Narayanan et al.
REVIEWS IN THE NEUROSCIENCES (2013)
The cholinergic system and Parkinson disease
Nicolaas I. Bohnen et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Mild Cognitive Impairment in Parkinson's Disease
Dag Aarsland et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2011)
Amyloid-β and τ biomarkers in Parkinson's disease-dementia
Mariateresa Buongiorno et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
The Effects of Rasagiline on Cognitive Deficits in Parkinson's Disease Patients Without Dementia: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Hasmet A. Hanagasi et al.
MOVEMENT DISORDERS (2011)
Executive functions in Parkinson's disease: Systematic review and meta-analysis
Aleksandra Kudlicka et al.
MOVEMENT DISORDERS (2011)
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Benedicte Ballanger et al.
ARCHIVES OF NEUROLOGY (2010)
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease
Sandro Fenu et al.
BEHAVIOURAL PHARMACOLOGY (2009)
Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
Susan H. Fox et al.
MOVEMENT DISORDERS (2009)
An expert opinion on safinamide in Parkinson's disease
Marco Onofrj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease
Doron Merims et al.
PARKINSONISM & RELATED DISORDERS (2008)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
Metabotropic glutamate receptors in the basal ganglia motor circuit
PJ Conn et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Pathophysiology of motor fluctuations in Parkinson's disease
K Widnell
MOVEMENT DISORDERS (2005)
Dementia in Parkinson's disease: cause and treatment
M Emre
CURRENT OPINION IN NEUROLOGY (2004)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Dopamine and cognitive function
B Pillon et al.
CURRENT OPINION IN NEUROLOGY (2003)
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study
F Bandini et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Share Paper
